136 related articles for article (PubMed ID: 21807054)
1. Reconstituted complexes of mycobacterial HSP70 and EBV LMP2A-derived peptides elicit peptide-specific cytotoxic T lymphocyte responses and anti-tumor immunity.
Liu G; Yao K; Wang B; Zhou F; Chen Y; Li L; Chi J; Peng G
Vaccine; 2011 Oct; 29(43):7414-23. PubMed ID: 21807054
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of Epstein-Barr virus associated malignancies using mycobacterial HSP70 and LMP2A356-364 epitope fusion protein.
Liu G; Yao K; Wang B; Chen Y; Zhou F; Guo Y; Xu J; Shi H
Cell Mol Immunol; 2009 Dec; 6(6):423-31. PubMed ID: 20003818
[TBL] [Abstract][Full Text] [Related]
3. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies.
Khanna R; Burrows SR; Moss DJ; Silins SL
J Virol; 1996 Aug; 70(8):5357-62. PubMed ID: 8764046
[TBL] [Abstract][Full Text] [Related]
4. Computational prediction and identification of Epstein-Barr virus latent membrane protein 2A antigen-specific CD8+ T-cell epitopes.
Wang B; Yao K; Liu G; Xie F; Zhou F; Chen Y
Cell Mol Immunol; 2009 Apr; 6(2):97-103. PubMed ID: 19403058
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells.
Xu JJ; Yao K; Yu CJ; Chen X; Lu MP; Sun H; Li BZ; Ding CN; Zhou F
Auris Nasus Larynx; 2006 Dec; 33(4):441-6. PubMed ID: 16934422
[TBL] [Abstract][Full Text] [Related]
6. EBV LMP2A-specific T cell immune responses elicited by dendritic cells loaded with LMP2A protein.
Chen Y; Sun H; Liu G; Wang B; Wang F; Sun B; Yao K
Cell Mol Immunol; 2009 Aug; 6(4):269-76. PubMed ID: 19728928
[TBL] [Abstract][Full Text] [Related]
7. Induction of T-cell immunity against Epstein-Barr virus-associated tumors by means of adenovirally transduced dendritic cells.
Sun H; Yao K; Chen Y; Zhou F
Chin Med J (Engl); 2004 Oct; 117(10):1558-63. PubMed ID: 15498383
[TBL] [Abstract][Full Text] [Related]
8. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.
Lee SP; Thomas WA; Murray RJ; Khanim F; Kaur S; Young LS; Rowe M; Kurilla M; Rickinson AB
J Virol; 1993 Dec; 67(12):7428-35. PubMed ID: 7693972
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.
Duraiswamy J; Sherritt M; Thomson S; Tellam J; Cooper L; Connolly G; Bharadwaj M; Khanna R
Blood; 2003 Apr; 101(8):3150-6. PubMed ID: 12468425
[TBL] [Abstract][Full Text] [Related]
10. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
Lee SP; Tierney RJ; Thomas WA; Brooks JM; Rickinson AB
J Immunol; 1997 Apr; 158(7):3325-34. PubMed ID: 9120290
[TBL] [Abstract][Full Text] [Related]
11. Three immunoproteasome-associated subunits cooperatively generate a cytotoxic T-lymphocyte epitope of Epstein-Barr virus LMP2A by overcoming specific structures resistant to epitope liberation.
Ito Y; Kondo E; Demachi-Okamura A; Akatsuka Y; Tsujimura K; Tanimoto M; Morishima Y; Takahashi T; Kuzushima K
J Virol; 2006 Jan; 80(2):883-90. PubMed ID: 16378990
[TBL] [Abstract][Full Text] [Related]
12. The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma.
Jones K; Wockner L; Brennan RM; Keane C; Chattopadhyay PK; Roederer M; Price DA; Cole DK; Hassan B; Beck K; Gottlieb D; Ritchie DS; Seymour JF; Vari F; Crooks P; Burrows SR; Gandhi MK
Clin Exp Immunol; 2016 Feb; 183(2):206-20. PubMed ID: 26422112
[TBL] [Abstract][Full Text] [Related]
13. Potent dendritic cell vaccine loaded with latent membrane protein 2A (LMP2A).
Chen Y; Yao K; Wang B; Qing J; Liu G
Cell Mol Immunol; 2008 Oct; 5(5):365-72. PubMed ID: 18954560
[TBL] [Abstract][Full Text] [Related]
14. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
[TBL] [Abstract][Full Text] [Related]
15. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
Khanna R; Burrows SR; Nicholls J; Poulsen LM
Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
[TBL] [Abstract][Full Text] [Related]
16. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease.
Su Z; Peluso MV; Raffegerst SH; Schendel DJ; Roskrow MA
Eur J Immunol; 2001 Mar; 31(3):947-58. PubMed ID: 11241300
[TBL] [Abstract][Full Text] [Related]
17. Delayed-type hypersensitivity (DTH) immune response related with EBV-DNA in nasopharyngeal carcinoma treated with autologous dendritic cell vaccination after radiotherapy.
Li F; Song D; Lu Y; Zhu H; Chen Z; He X
J Immunother; 2013 Apr; 36(3):208-14. PubMed ID: 23502768
[TBL] [Abstract][Full Text] [Related]
18. Chimerically fused antigen rich of overlapped epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a potential vaccine and diagnostic agent.
Lin X; Chen S; Xue X; Lu L; Zhu S; Li W; Chen X; Zhong X; Jiang P; Sename TS; Zheng Y; Zhang L
Cell Mol Immunol; 2016 Jul; 13(4):492-501. PubMed ID: 25864917
[TBL] [Abstract][Full Text] [Related]
19. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma.
Gahn B; Siller-Lopez F; Pirooz AD; Yvon E; Gottschalk S; Longnecker R; Brenner MK; Heslop HE; Aguilar-Cordova E; Rooney CM
Int J Cancer; 2001 Sep; 93(5):706-13. PubMed ID: 11477583
[TBL] [Abstract][Full Text] [Related]
20. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
